AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases, has shared a letter to shareholders from chair, president and CEO James Sapirstein. The letter noted that AZRX is on track to launch its niclosamide programs in the clinic, noting that just this month the company announced the initiation of RESERVOIR, its Phase 2 clinical trial of niclosamide for the treatment of COVID-19-related gastrointestinal infections; the company also established an agreement with PPD Inc. (“PPD”), a leading clinical research organization, to manage the upcoming Phase 1b/2a ICI-AC trial, planned for Q2 2021. Sapirstein also shared that the company is continuing the development of MS1819 as a potential treatment for exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis (“CF”) and is anticipating to release topline data from its Phase 2 combination therapy trial using MS1819 in combination with pancreatic enzyme replacement therapy (“PERT”), which is the current standard of care. The letter noted that the company continues to believe that MS1819 could replace PERT as the gold standard treatment for EPI in patients with CF and chronic pancreatitis (“CP”). The letter also provided further information about MS1819, the company’s most advanced clinical asset. The letter also provided detailed information about the two niclosamide clinical trials scheduled for 2021 and offered a summary of financial information for Q1 2021. “These are exciting times for AzurRx, and we anticipate several catalysts on the horizon,” said AzurRx BioPharma chair, president and CEO James Sapirstein in the letter. “I look forward to working with my management team and fellow board members to execute a business and clinical strategy that has the potential to transform AzurRx and generate substantial returns for our shareholders. We will continue to pursue our efforts to drive long-term shareholder value by delivering safe and effective GI therapies for patients who need them the most, raising our global visibility and broadening our shareholder base. We look forward to continuing what has been a productive 2021.”
To view the full letter, visit https://ibn.fm/cbezg
About AzurRx BioPharma Inc.
AzurRx BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases. The company has a pipeline of three gut-restricted GI assets. The first is MS1819, a recombinant lipase biologic for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis and chronic pancreatitis, with two ongoing phase 2 clinical trials. The other two are clinical-stage therapies using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor: FW-420, for the treatment of grade 1 immune checkpoint inhibitor associated colitis (“ICI-AC”) and diarrhea in oncology patients, and FW-1022, for the treatment of COVID-19 gastrointestinal infections. The company is headquartered in Delray Beach, Florida, with clinical operations in Hayward, California. For more information, visit the company’s website at www.AzurRx.com.
NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at https://ibn.fm/AZRX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.